Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.52 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.51 |
| ▸ | EIF4H | Q15056 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14127360 | 1.00 | MAPT (0.58) | MAPTKDM4ECYP1A2CYP2A6PABPC1 | |
| SCHEMBL29971960 | 1.00 | MAPT (0.58) | MAPTKDM4ECYP1A2CYP2A6PABPC1 | |
| SCHEMBL4004887 | 0.98 | MAPT (0.56) | MAPTKDM4ECYP1A2CYP2A6PABPC1 | |
| Boric Acid SCHEMBL21047561 | 0.92 | MAPT (0.50) | MAPTKDM4ECYP1A2CYP2A6PABPC1 | |
| Glyoxylate SCHEMBL27986142 | 0.84 | PABPC1 (0.51) | MAPTKDM4ECYP1A2PABPC1EIF4H | |
| SCHEMBL29566907 | 0.84 | MAPT (0.56) | MAPTKDM4ECYP1A2CYP2A6MEN1 | |
| SCHEMBL201545 | 0.84 | MAPT (0.56) | MAPTKDM4ECYP1A2CYP2A6MEN1 | |
| Fluoroacetate SCHEMBL27765257 | 0.83 | PABPC1 (0.53) | MAPTKDM4ECYP1A2PABPC1EIF4H | |
| Ammonia Solution, Strong SCHEMBL2421811 | 0.82 | MAPT (0.55) | MAPTKDM4ECYP1A2CYP2A6MEN1 | |
| SCHEMBL4471031 | 0.82 | MAPT (0.55) | MAPTKDM4ECYP1A2CYP2A6MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 324 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114105984-B | Method for preparing indolizine type corrosion inhibitor | 中国石油大学(华东) | 2023-08-25 | — | — | CN | claimed |
| CN-114105984-A | Preparation method of indolizine corrosion inhibitor | 中国石油大学(华东) | 2022-03-01 | — | — | CN | claimed |
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | BASF SE (DE) | 2019-03-05 | — | — | US | claimed |
| EP-2955173-B1 | 1,2-BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2017-10-04 | — | — | EP | claimed |
| US-9603834-B2 | 1,2- bis-sulfonamide derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2017-03-28 | — | — | US | claimed |
| US-20170012208-A1 | ORGANIC SEMICONDUCTOR FORMULATIONS | USINVEST LLC | 2017-01-12 | — | — | US | claimed |
| US-20160228407-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. | 2016-08-11 | — | — | US | claimed |
| EP-2955173-A1 | NOVEL 1,2-BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2015-12-16 | — | — | EP | claimed |
| EP-2651901-B1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2015-05-27 | — | — | EP | claimed |
| US-20140221351-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2014-08-07 | — | — | US | claimed |
| US-7220414-B2 | Degradable polyacetal polymers | A.P. PHARMA, INC. (US) | 2007-05-22 | — | — | US | claimed |
| EP-1701741-A2 | COMPLEXES HAVING ADJUVANT ACTIVITY | Polytherics Limited (GB) | 2006-09-20 | — | — | EP | claimed |
| WO-2005065712-A2 | COMPLEXES HAVING ADJUVANT ACTIVITY | POLYTHERICS LIMITED (GB) | 2005-07-21 | — | — | WO | claimed |
| EP-1210093-A4 | DEGRADABLE POLYMERS | POLYTHERICS LTD (GB) | 2005-01-12 | — | — | EP | claimed |
| US-6828412-B1 | Degradable polymers | SCHOOL OF PHARMACY, UNIVERSITY OF LONDON (GB) | 2004-12-07 | — | — | US | claimed |
| EP-1418811-A1 | SELECTIVE HERBICIDES BASED ON SUBSTITUTED CYCLIC KETO-ENOLS AND SAFENERS | Bayer CropScience AG (DE) | 2004-05-19 | — | — | EP | claimed |
| WO-2003013249-A1 | SELECTIVE HERBICIDES BASED ON SUBSTITUTED CYCLIC KETO-ENOLS AND SAFENERS | BAYER CROPSCIENCE AG (DE) | 2003-02-20 | — | — | WO | claimed |
| EP-1210093-A1 | DEGRADABLE POLYMERS | SCHOOL OF PHARMACY, UNIVERSITY OF LONDON (GB) | 2002-06-05 | — | — | EP | claimed |
| WO-2001017515-A1 | DEGRADABLE POLYMERS | SCHOOL OF PHARMACY, UNIVERSITY OF LONDON (GB) | 2001-03-15 | — | — | WO | claimed |
| US-4795621-A | CATALYST OF QUINOLINE COMPOUND AND METAL COMPOUND | SHIN NISSO KAKO CO., LTD. (JP) | 1989-01-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228407-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CXCR2, CCR2, CX3CR1 | MAPT 4542/4885KDM4E 4794/4885CYP1A2 3836/4885 |
| US-20140221351-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CXCR2, CCR2, CX3CR1 | MAPT 4542/4885KDM4E 4794/4885CYP1A2 3836/4885 |
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | STOM, SPOP, TTR | MAPT 150/4885KDM4E 3646/4885CYP1A2 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.